Close
Dicot moves forward with a new patent application

Press release: Uppsala, June 10, 2022. Dicot AB is developing the drug candidate LIB-01, a potency drug to better treat erectile dysfunction and premature ejaculation. The company announces that it is now moving forward with a new patent application in order to extend the patent protection around the company's drug candidate until at least 2042.

Dicot is developing a new potency drug that aims to be the first choice for the treatment of erectile dysfunction and premature ejaculation. At the beginning of 2022, Dicot announced that several new patent opportunities were identified and that they would be protected as trade secrets, in order to convert these into patents at the right point of time. The goal of the strategy is to ensure the longest possible market exclusivity and revenue opportunity for LIB-01 and thereby the shareholder value.

Dicot today announces that the company will proceed with one of these trade secrets and that a new patent application is being prepared. The purpose is to patent both new manufacturing methods and intermediates (various chemical compounds) during the manufacture of the drug substance in Dicot's product candidate LIB-01. The patent application will be submitted after the summer. Patents provide 20 years of market exclusivity from the time the application is submitted.

"Dicot's IP-portfolio is already a unique asset in the billion market for sexual dysfunctions and with additional new patents we will significantly increase the long-term value of our product candidate through market exclusivity until at least 2042. This means we execute according to plan, based on our IP strategy. ", says Elin Trampe, CEO of Dicot.

For further information, please contact:

Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.

2022-06-29
Regulatory

Press release: Uppsala, June 29, 2022. Dicot AB is developing a new potency drug aiming at becoming the first choice of treatment. The company announces today that the newly developed oral formulation demonstrates good results in a recently conducted efficacy study.

2022-06-17
Regulatory

Press release: Uppsala, June 17, 2022.

Dicot AB (publ) ("Dicot" or the "Company") announces the outcome regarding exercising of warrants of series TO 3. Holders of warrants exercised 34,202,814 warrants, corresponding to approximately 90 percent of the number of outstanding warrants, for subscription of 34,202,814 shares at a subscription price of SEK 0.29 per share. Through the exercise of the warrants, Dicot will receive approximately SEK 10 million before issue costs.

2022-06-13
Regulatory

Press release: Uppsala, June 13, 2022. The company announces that members in the board and management are increasing their shareholding in the company.

2022-06-13

Today, June 13, 2022, is the last day of trading with the warrants of series TO 3. The subscription period for the warrants of series TO 3 will continue up until June 15, 2022.

2022-06-10

Press release: Uppsala, June 10, 2022. Dicot AB is developing the drug candidate LIB-01, a potency drug to better treat erectile dysfunction and premature ejaculation. The company announces that it is now moving forward with a new patent application in order to extend the patent protection around the company's drug candidate until at least 2042.

2022-06-09

Uppsala, June 9, 2022. Meet Dicot's CEO Elin Trampe at Småbolagsdagarna on Monday June 13 when she presents the company's development of a new potency drug and the latest advances. Among other things, she will talk about a newly started project with Uppsala University and raise the issue of the culture of silence among men with erectile dysfunction.

2022-06-01

Today on June 1, 2022, the subscription period for the warrants of series TO 3 issued in connection with the rights issue of units in Dicot AB (publ) during the fourth quarter of 2021. The subscription period lasts until June 15, 2022.

2022-05-31

Uppsala, May 31, 2022. Dicot AB is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. Dicot announces today that the company has entered a research collaboration with Uppsala University and the W. Szafer Institute of Botany of the Polish Academy of Sciences (PAS) to investigate a new technology to make starting material for production of the drug substance.

2022-05-29
Regulatory

Press release: Uppsala, May 29, 2022.

During the fourth quarter of 2021, Dicot AB (publ) (``Dicot`` or ``the Company``) conducted a rights issue of units, with one (1) unit consisting of three (3) new issued shares and three (3) free-of-charge warrants of series TO 3 (previously also named series 2021/2022). Those who subscribed for units during the subscription period between October 12, 2021, and October 27, 2021, therefore obtained three (3) additional warrants of series TO 3 per unit subscribed. Each warrant of series TO 3 entitles the holder to subscribe for one (1) new share in Dicot. The subscription price for subscription of shares using warrants will correspond to 70 percent of the average volume-weighted price of the Company's share according to Spotlight Stock market's official list during the period from May 16, 2022, up to and including May 27, 2022. However, the subscription price shall not be higher than 1.50 SEK or lower than 0.125 SEK (corresponding quota value of the Company's share). The average volume-weighted price of the Company's share during the measurement period amounted to approximately 0.41 SEK, hence, the subscription price has been set to 0.29 SEK per share.

2022-05-06
Regulatory

Press release: Uppsala, May 6, 2022. A summary of the Interim report January - March 2022, for Dicot AB (publ) is now available on the company website www.dicot.se 

First quarter 2022

  • Net sales amounts to kSEK 0 (0)
  • Earnings for the period amounts to kSEK -9,346 (-8,468)
  • Earnings per share SEK -0.09 (-0.19)
1
2
...
17
>>